Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis

详细信息    查看全文

• 作者：Liang Wu (1)
  Fengliang Wang (2)
  Ruobing Xu (1)
  Simin Zhang (1)
  Xianzhen Peng (1)
  Yan Feng (1)
  Jianming Wang (1)
  Cheng Lu (2)
  
• 关键词：Breast cancer ; BRCA1 ; Methylation ; Prognosis ; Survival ; Meta ; analysis
• 刊名：Breast Cancer Research and Treatment
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：142
• 期：3
• 页码：619-627
• 全文大小：
• 作者单位：Liang Wu (1)
  Fengliang Wang (2)
  Ruobing Xu (1)
  Simin Zhang (1)
  Xianzhen Peng (1)
  Yan Feng (1)
  Jianming Wang (1)
  Cheng Lu (2)
  
  1. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People Republic of China
  2. Department of Breast, Nanjing Maternity and Child Health Hospital of Nanjing Medical University, Nanjing, People Republic of China
  
• ISSN：1573-7217

文摘

The inactivation of BRCA1 by epigenetic alterations is a critical event in breast tumorigenesis, which may potentially be used as a prognostic marker for patients with breast cancer. The present study systematically reviewed the promoter methylation of BRCA1 and its relationship to the clinical outcomes of breast cancer patients. We performed a meta-analysis following the PRISMA guideline. Relevant articles were identified by searching PubMed, Web of Science and Embase database until August 2013. The pooled hazard ratio (HR) and 95% confidence interval (CI) were applied to estimate the effect of BRCA1 methylation. Random or fixed effect model was chosen based on the heterogeneity analysis. A total of 3,205 patients from nine eligible studies were included in the meta-analysis. BRCA1 methylation was found to be significantly correlated with a poor overall survival of breast cancer, with the combined HR (95% CI) of 2.02 (1.35.03). After adjusting for potential confounders using the Cox regression model, the pooled HR (95% CI) of BRCA1 methylation on patientsoverall survival was 1.38 (1.04.84). If we used the disease-free survival as the outcome, the combined HR (95% CI) was 2.89 (1.73.83) for univariate analysis and 3.92 (95% CI 1.490.32) for multivariate analysis, respectively. Subgroup analysis of specimen types revealed that the pooled HR (95% CI) for overall survival was 1.48 (1.22.81) when using formalin-fixed paraffin-embedded (FFPE) specimen and 1.38 (0.161.84) when using fresh frozen tissues. As for the disease-free survival, the pooled HR (95% CI) was 2.47 (1.33.58) when using FFPE specimen and 2.78 (1.47.28) when using fresh frozen tissues. As a conclusion, the present meta-analysis provides evidence that BRCA1 methylation is associated with a poor survival of breast cancer patients. Our findings underscore the clinical relevance of aberrant epigenetic alteration as a promising biomarker for the prognosis of human cancers.